AllPennyStocks.com CAPR Stock Surges 67% After-Hours — Is There Still A Path Forward For Deramiocel?
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

CAPR Stock Surges 67% After-Hours — Is There Still A Path Forward For Deramiocel?

CEO Marbán said Capricor remains focused on delivering the therapy to patients and is working closely with the FDA on a path forward centered on improvements in upper-limb skeletal muscle function demonstrated in trials.

Other Penny Stock Movers

Casino Tables Are Going Social, and This Microcap Just Expanded Its Reach
Canadian Defense Tech Firm Jumps 92% as Government Revenue Boosts Margins
Fiji Gold Explorer Gains 30% as Field Access Clears and Strategic Backing Closes
Most Popular
{{ index + 1 }}


Back to Top